89283-73-8

Upstream product

• 110-61-2 butanedinitrile 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 1607024-72-5 2-[5-(4-chloro-3-methoxyphenyl)-7-oxo-4H,7H-pyrazolo[1,5-a]pyrimidin-3-yl]acetonitrile 
• 1607024-73-6 2-[5-(4-chloro-3-methoxyphenyl)-7-oxo-4H,7H-pyrazolo[1,5-a]pyrimidin-3-yl]acetic acid 
• 1607023-30-2 2-[5-(4-chloro-3-methoxyphenyl)-7-oxo-4H,7H-pyrazolo[1,5-a]pyrimidin-3-yl]-N-ethylacetamide 
• 1607023-31-3 2-(5-(4-chloro-3-methoxyphenyl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-3-yl)-N-methylacetamide 
• 169882-17-1 1-(2-bromo-4,6-dimethoxyphenyl)-3-cyano-4,6-dimethyl-7-azaindole 
• 59661-20-0 (E,Z)-2-(2,3-dicyanopropen-1-ylamino)benzoic acid methyl ester 
• 59661-51-7 5-oxo-4,5-dihydropyrrolo[1,2-a]quinazoline-2-carbonitrile 
• 1380740-72-6 3-cyano-5-methyl-1H-pyrrolo[2,3-b]pyridine-4-carboxylic acid 
• 269726-49-0 2-amino-1-tert-butyl-4-cyanopyrrole 
• 1000815-86-0 5-amino-1-(2-chloro-6-fluoro-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carbonitrile 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY

A compound represented by the following general formula (1) or a salt thereof. R1 represents a halogen atom and so on; R2 and R3 each represent a hydrogen atom and so on; R4 and R5 each represent a hy

PREPARATION OF SUBSTITUTED-4,5-DIHYDROPYRROLO[4,3,2-de][2,6]NAPHTHYRIDIN-3(1H)-ONES

Disclosed are materials and methods for preparing substituted 4,5-dihydropyrrolo[4,3,2-de][2,6]naphthyridin-3(1H)-ones of formula (1), Compounds of formula (1) inhibit one or more members of the Janus Kinase (JAK) family of cytoplasmic protein tyrosine kinases, and are useful for treating disorders, diseases, and conditions associated with the immune system, inflammation, and abnormal cell growth.

1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof

Provided are 1-aryl-5-alkyl pyrazole compounds, of formula (I): wherein: R1 is hydrogen, cyano, halogen, R8, formyl, -C(O)R8, -C(O)OR8, -C(O)NR9R10, or -C(S)NH2; R2 is R2 or -S(O)mR11; R3 is methyl, ethyl or C1-C4 haloalkyl; R4, R5 and R7 are independently hydrogen, halogen, alkyl, haloalkyl, cyano or nitro; R6 is halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy, cyano, nitro, -C(O)R12, -S(O)nR12 or SF5; Z is a nitrogen atom or C-R13; R8 is alkyl, haloalkyl, cycloalkyl or halocycloalkyl; R9 is hydrogen, alkyl, haloalkyl or alkoxy; R10 is hydrogen, alkyl, haloalkyl or alkoxy; R11 is alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl or cycloalkyl; R12 is alkyl or haloalkyl; R13 is hydrogen, halogen, cyano, nitro, alkyl, haloalkyl, alkoxy or haloalkoxy; m is 0, 1 or 2; and n is 0, 1 or 2; or a salt thereof, the method of making compounds of formula (I) and the use of these compounds against ectoparasites, endoparasites and pests.